




# XXXII CONGRESSO BRASILEIRO DE CIRURGIA




## CÂNCER DO PÂNCREAS Situação atual do tratamento cirúrgico

**Orlando Jorge M. Torres**

Professor Titular

Chefe do Serviço de Cirurgia do Aparelho Digestivo  
Universidade Federal do Maranhão



**TABLE 33-20**

World Health Organization classification of primary tumors of the exocrine pancreas

## A. Benign

1. Serous cystadenoma (16%)
2. Mucinous cystadenoma (45%)
3. Intraductal papillary-mucinous adenoma (32%)
4. Mature cystic teratoma

## B. Borderline

1. Mucinous cystic tumor with moderate dysplasia
2. Intraductal papillary mucinous tumor with moderate dysplasia
3. Solid pseudopapillary tumor

## C. Malignant

1. Ductal adenocarcinoma
2. Serous/mucinous cystadenocarcinoma (29%)
3. Intraductal mucinous papillary tumor

# Neoplasias císticas do pâncreas

IPMN

Frantz

|   | Serous cystic neoplasm     | Mucinous cystic neoplasm | Intraductal papillary mucinous neoplasm | Solid-pseudopapillary neoplasm |
|---|----------------------------|--------------------------|---|--------------------------------|
| Mean age (years)                        | 65                         | 45                       | 63                                      | 28                             |
| Gender (male:female)                    | 30:70                      | 10:90                    | 60:40                                   | 10:90                          |
| Location within the pancreas            | Evenly distributed         | Body and tail            | Head                                    | Evenly distributed             |
| Cyst contents                           | Watery straw colored fluid | Thick tenacious mucin    | Thick tenacious mucin                   | Hemorrhagic                    |
| Connectivity to larger pancreatic ducts | No                         | No                       | Yes                                     | No                             |
| Epithelial lining                       | Cuboidal, glycogen rich    | Columnar, mucinous       | Columnar, mucinous                      | Noncohesive uniform cells      |
| Stroma                                  | Nonspecific                | Ovarian-type             | Nonspecific                             | Delicate capillaries           |

# Neoplasias císticas do pâncreas

Table 2 Differential diagnosis of cystic pancreatic lesions

|                     | SCA           | MCN              | IPMN          | SPN           | Pseudocyst    |
|---------------------|---------------|------------------|---------------|---------------|---------------|
| Prevalent age       | Middle age    | Middle age       | Elderly       | Young         | Variable      |
| Sex                 | Mostly female | Mostly female    | Male > female | Mostly female | Male > female |
| Presentation        | Mass/pain     | Mass/pain        | Pancreatitis  | Mass/pain     | Pain          |
| Location            | Evenly        | Body/tail        | Head          | Evenly        | Evenly        |
| Malignant potential | Very low      | Moderate to high | Low to high   | Low           | None          |

SCA: Serous cystadenoma; MCN: Mucinous cystic neoplasm; IPMN: Intraductal papillary mucinous neoplasia; SPN: Solid pseudopapillary neoplasm.

# Neoplasias císticas do pâncreas

**Table 3 Cystic fluid analysis in cystic pancreatic diseases**

|         | <b>SCA</b> | <b>MCN</b>    | <b>MCAC</b>   | <b>Pseudocyst</b> |
|---------|------------|---------------|---------------|-------------------|
| CEA     | Low        | High          | High          | Low               |
| CA125   | Variable   | Variable      | High          | Low               |
| CA19-9  | Variable   | Variable-high | Variable-high | Variable          |
| Amylase | Low-high   | Low-high      | Low-high      | High              |
| Lipase  | Low        | Low           | Low           | High              |

SCA: Serous cystadenoma; MCN: Mucinous cystic neoplasm; MCAC: Mucinous cystadenocarcinoma

# Neoplasias císticas do pâncreas

**Table 1.** WHO classification (2010) of pancreatic cystic neoplasms

| Serous cystic neoplasm   | Mucinous cystic neoplasm                                   | Intraductal papillary mucinous neoplasm                                 | Solid pseudopapillary neoplasm  |
|--|--|---|---------------------------------|
| Serous cystadenoma<br>– Serous microcystic adenoma<br>– Serous oligocystic adenoma | Mucinous cystadenoma                                       | Intraductal papillary mucinous adenoma                                  | Solid pseudopapillary neoplasm  |
| Serous cystadenocarcinoma  | Mucinous cystic neoplasm with moderate dysplasia           | Intraductal papillary mucinous neoplasm with moderate dysplasia         | Solid pseudopapillary carcinoma |
|  | Mucinous cystadenocarcinoma<br>– Noninvasive<br>– Invasive | Intraductal papillary mucinous carcinoma<br>– Noninvasive<br>– Invasive |                                 |

# Neoplasias císticas do pâncreas

**Table 2.** Imaging and cyst fluid characteristics of cystic lesions of pancreas

| Pancreatic cystic lesion | Imaging characteristics   | Fluid analysis   |
|--------------------------|---|--|
| Pseudocyst               | Usually associated with pancreatitis<br>Unilocular<br>Uniform, enhancing, well-defined walls<br>Peripancreatic inflammation<br>May communicate with pancreatic duct | ↓ Viscosity<br>↓ Lipase<br>↑ Amylase<br>↔/↑ CEA levels |
| Serous cystic lesion     | Microcystic<br>Honeycomb pattern of microlacunae<br>Stellate scar<br>Central calcifications – starburst appearance  | ↓ Viscosity<br>↓ CEA<br>↓ CA19-9<br>↓ Amylase          |
| Mucinous cystic lesion   | Typically unilocular but can be multilocular<br>Body/tail of the pancreas<br>Macrocytic<br>No duct communication<br>Peripheral ‘eggshell’ calcifications            | ↑ Viscosity<br>↑ CEA<br>↑ CA19-9<br>↓ Amylase          |
| IPMN                     | Macrocytic<br>Ductal involvement<br>– Main duct: dilated, tortuous main pancreatic duct<br>– Branch duct: lobulated lesion with grape-like clusters                 | ↑ Viscosity<br>↑ CEA<br>↑ Amylase                      |

# Fatores de risco

- Idade
- Sexo masculino
- Raça negra
- Judeus (descendentes)

# Fatores de risco

## Hereditariedade (10%)

Síndrome de Lynch

Síndrome de Peutz-Jeghers

Pancreatite hereditária

Câncer de mama familiar

Câncer de ovário familiar

## Tabagismo

## Diabetes

## Pancreatite crônica

**Table 60.1** General features of pancreatic tumors.

| Type                                    | Frequency | Prognosis     |
|---|-----------|---------------|
| <i>Solid tumors</i>                     |           |               |
| Ductal adenocarcinoma and variants      | 90%       | Unfavorable   |
| Acinar cell carcinoma                   | 1%        | Unfavorable*  |
| Pancreatoblastoma                       | <1%       | Unfavorable*  |
| Endocrine tumors                        | 2%        | Intermediate† |
| Nonepithelial tumors                    | Rare      | Intermediate† |
| <i>Cystic tumors</i>                    |           |               |
| Intraductal papillary mucinous neoplasm | 2%        | Good          |
| Mucinous cystic neoplasm                | 1%        | Good          |
| Serous cystic neoplasm                  | 1%        | Good          |
| Solid pseudopapillary neoplasm          | <1%       | Good          |
| Other cystic tumors                     | 1%        | Intermediate† |
| Nonepithelial lesions and tumors        | Rare      | Intermediate† |

# Neoplasias císticas do pâncreas

## Histological Classification of Pancreatic Cystic Tumours

### Benign

Acinar cell cystadenoma

Serous cystadenoma

### Premalignant lesions

Intraductal papillary mucinous neoplasms with low- or intermediate-grade dysplasia

Intraductal papillary mucinous neoplasms with high-grade dysplasia

Intraductal tubulopapillary neoplasms

Mucinous cystic neoplasms with low- or intermediate-grade dysplasia

Mucinous cystic neoplasms with high-grade dysplasia

### Malignant

Acinar cell cystoadenocarcinoma



Intraductal papillary mucinous neoplasms with an associated invasive carcinoma

Mucinous cystic neoplasms with an associated invasive carcinoma


Serous cystoadenocarcinoma

Solid-pseudopapillary neoplasms


# Cistoadenoma seroso



# Cistoadenoma seroso



# Cistoadenoma seroso



# Cistoadenoma seroso

hospital  
São Domingos



# Cistoadenoma seroso



# Cistoadenoma seroso




CENPAT-H-2015-2208




# Lesões pré-malignas

- Lesões císticas pré-malignas
  - IPMN (Neoplasia mucinosa papilar intraductal)
  - MCN (Neoplasia mucinosa cística)
- Neoplasia intra-epitelial pancreática (PanIN)



# IPMN Neoplasia mucinosa papilar intraductal



# IPMN Neoplasia mucinosa papilar intraductal



# Neoplasia mucinosa cística




# Neoplasia mucinosa cística




## Neoplasia mucinosa cística




# Neoplasia intra-epitelial pancreática




# Neoplasia sólida pseudopapilar (Frantz)



# Neoplasia mucinosa papilar intraductal (IPMN)



# Neoplasia mucinosa papilar intraductal (IPMN)



# Suspeita clínica

- Icterícia obstrutiva
- Perda de peso > 10% (sem explicação)
- Dor abdominal ou lombar (sem explicação)
- Dispepsia
- Diabetes mellitus (súbito) sem fatores predisponentes
- Pancreatite idiopática
- Esteatorréia (sem explicação)

# Apresentação clínica

□ Depende da localização

Cabeça

Corpo

Cauda

# Estado atual

## Pré-operatório

Necessidade de biópsia

Quimioterapia neoadjuvante

## Escolha da via de acesso

Videolaparoscopia

## Transoperatório

Ressecção vascular

Preservação gástrica (SSPPD)

Linfadenectomia

Anastomose pancreática

Drenagem abdominal profilática

## Pós-operatório



Não é hepatite!

## Achados clínicos

- Icterícia
- Hepatomegalia
- Vesícula palpável (Courvoisier)
- Caquexia
- Tromboflebite migratória
- Adenopatia

SuprACLAVICULAR (Virchow)

Periumbilical (Irmã Maria José)

Pelve (Prateleira de Blumer)

## Marcador tumoral

### CA 19-9

- Detecta carga tumoral
- Nível associado com ressecabilidade
  - < 100 U/mL      60-80%
  - 100-400 U/mL    20-30%
  - > 400 U/mL     irressecável
- Associado com sobrevida
  - < 37 U/mL       20-40 meses
- Queda no pós-operatório
  - < 37 U/mL      prolongada
- Elevação no pós-operatório
  - Recorrência

### Limitações

Apenas em pacientes com Lewis

Falso negativo 5-10%

### Falso positivo 10-60%

Colangite

Hepatite

Pancreatite

Icterícia obstrutiva

### Outras neoplasias

Esôfago

Estômago

Colo-retal


**Table 67.2** Sensitivity and specificity of serum CA19-9 assay in diagnosing pancreatic cancer with different cutoff levels. (From ref. 22 with permission.)

| CA19-9 (U/mL) | Sensitivity (%) | Specificity (%) |
|---------------|-----------------|-----------------|
| 15            | 92              | 60              |
| 37            | 85              | 81              |
| 75            | 80              | 90              |
| 250           | 70              | 95              |
| 500           | 60              | 98              |
| 1000          | 40              | 99              |

# Exames de imagem

- Ultrassonografia
- Tomografia com contraste
- Ressonância Nuclear Magnética
- CPRE (Colangiopancreatografia retrógrada endoscópica)
- Ecoendoscopia

# ☐ Ultrassonografia




- Lesão focal na cabeça do pâncreas

## Tomografia com contraste




- Vesícula de Courvoisier



- Dilatação da VB intra-hepática


## Ressonância nuclear magnética




## Ressonância nuclear magnética



# Ecoendoscopia




- Extensão da lesão
- Invasão vascular





A **Tipo I - Obstrução do DPP**

**Tipo V Sinal do Ducto duplo**




**. Tipo II Estenose segmentar do DPP**



**Tipo IV - Ramificações laterais**





**Tipo III - Estreitamento difuso**



# Estadiamento

- Ultrassonografia
- Tomografia com contraste
- Ressonância Nuclear Magnética
- Ecoendoscopia
- PET CT
- Laparoscopia
- Exploração








**Figure 48.1**

Borderline resectable low-attenuation mass in the head of the pancreas that extends along the anterior margin of the superior mesenteric vein (SMV; *dashed arrow*), with an intact fat plane between the SMV and superior mesenteric artery



**Figure 48.2**

Dual-phase multidetector computed tomography (MDCT) image of a locally advanced, unresectable pancreatic cancer involving the SMA (*solid arrow*) and its branches (*dashed arrow*)

# Laparoscopia

**TABLE 33-19** Findings at exploration

Findings contraindicating resection

- Liver metastases (any size)
- Celiac lymph node involvement
- Peritoneal implants
- Hepatic hilar lymph node involvement

Findings not contraindicating resection

- Invasion at duodenum or distal stomach
- Involved peripancreatic lymph nodes
- Involved lymph nodes along the porta hepatis that can be swept down with the specimen

**Table 2**  
**Definitions of borderline resectable pancreatic cancer**

| Vessel Involved      | MDACC   | AHPBA/SSO/<br>SSAT  | NCCN/ISGPS   | Moffitt   |
|----------------------|---|---|--|---|
| SMA                  | Abutment  | Abutment  | Abutment   | Abutment  |
| CHA                  | Abutment or<br>short segment<br>encasement                  | Abutment or<br>short segment<br>encasement                                | Abutment<br>without<br>extension to<br>celiac or HA<br>bifurcation | Abutment or<br>short segment<br>encasement            |
| Celiac axis          | Abutment  | No abutment or<br>encasement  | No contact   | Not specified   |
| SMV-PV<br>confluence | Short-segment<br>occlusion<br>amenable to<br>reconstruction | Abutment,<br>encasement,<br>or occlusion<br>amenable to<br>reconstruction | Abutment or<br>encasement<br>amenable to<br>reconstruction         | Abutment or<br>encasement<br>amenable to<br>resection |

# Tratamento

## Duodenopancreatectomia

Apenas 20% são ressecáveis

## Quimioterapia

Neoadjuvante

Adjuvante

## Quimio-radioterapia

## Paliação

80% dos pacientes

Doença localmente avançada

Doença metastática

# Critérios de ressecabilidade

---

## *Resectable*

No distant metastases (liver, peritoneal, etc.)

No superior mesenteric, celiac, or hepatic artery encasement

Normal portography

## *Locally advanced resectable (borderline resectable)*

Abnormal portography but possibility of reconstruction

Tumor abutment on celiac or superior mesenteric artery

Invasion of stomach, colon, or mesocolon

## *Unresectable*

Distant metastases (liver, peritoneal, etc.)

Superior mesenteric, celiac, or hepatic artery encasement

Lymph node metastases outside the dissection field

Portal or superior mesenteric venous invasion with obstruction indicating impossibility of reconstruction


Severe concomitant disease

---


# Cirurgia

- Duodenopancreatectomia
  - Whipple clássica
  - Preservação pilórica
  - Preservação gástrica
- Via de acesso
  - Aberta
  - Laparoscópica
- Dois tempos distintos
  - Ressecção
  - Reconstrução

A



B



## THE OBITUARY OF THE PYLORUS-PRESERVING PANCREATODUODENECTOMY



*O obituário da duodenopancreatectomia com preservação pilórica*

Orlando Jorge Martins **TORRES**, Rodrigo Rodrigues **VASQUES**, Camila Cristina S. **TORRES**

From the Department of Surgery, Federal University of Maranhão, São Luiz, MA, Brazil

Pancreatoduodenectomy is the treatment of choice for patients with benign and malignant disease of pancreatic head. Classic pancreatoduodenectomy was described by Whipple originally and included distal hemigastrectomy. Pylorus-preserving pancreatoduodenectomy (pylorus-preserving) was popularized in the late 1970s for benign disease and it included full preservation of the pylorus. However, delayed gastric emptying after pylorus-preserving is a frustrating complication. Its incidence varying from 19% to 61% in previous series and it results in discomfort, prolonged length of stay and increases the risk of respiratory complications. Delayed gastric emptying contributes to increased hospital costs and decreased quality of life. There has been no evidence from prospective studies and meta-analyses to indicate the superiority of pylorus preserving in terms of quality of life or delayed gastric emptying<sup>2,4,5,7</sup>.

More recently, and mostly in Japan since the late 1990s, subtotal stomach-preserving pancreatoduodenectomy (stomach-preserving) in which the pyloric ring and 2 cm of the distal stomach only is removed with preservation of about 90% of the



Hayashibe A, et al. J Surg Oncol 2007;95:106-9.

## DUODENOPANCREATECTOMIAS: ANÁLISE DE 39 PACIENTES

### PANCREATICODUODENECTOMIES: ANALYSIS OF 39 PATIENTS

**Orlando Jorge Martins Torres, TCBC-MA<sup>1</sup>; Érica Sampaio Barbosa<sup>2</sup>; Noelia Dias Carneiro Barros<sup>2</sup>;  
Cristiany de Almeida Barros<sup>3</sup>; Edson Dener Zandonadi Ferreira<sup>2</sup>; Herquimas Costa Pereira, ACBC-MA<sup>3</sup>**


---

**RESUMO:** **Objetivo:** Pretendemos neste estudo analisar 39 pacientes submetidos à duodenopancreatectomia. **Método:** No período de julho de 1998 a março de 2004, trinta e nove pacientes foram submetidos a duodenopancreatectomia no Hospital Universitário da Universidade Federal do Maranhão. Foram analisados os dados epidemiológicos, o quadro clínico, os métodos radiológicos, as indicações da operação e as complicações encontradas. **Resultados:** Havia 22 pacientes do sexo masculino (56,4%) e 17 pacientes do sexo feminino (43,6%) com média de idade de 54,9 anos (variação de 21-82 anos). O exame radiológico mais utilizado foi a tomografia computadorizada. O diagnóstico histológico definitivo revelou adenocarcinoma periampolar em 35 pacientes (89,7%), pancreatite crônica (três pacientes – 7,7%) e adenocarcinoma colo-retal (um paciente – 2,6%). O adenocarcinoma periampolar mais freqüente foi o carcinoma ductal do pâncreas (27 pacientes – 69,2%), seguido por carcinoma de papila de Vater (cinco


**Table 2.** Indications

| Indication                 | First 1,000 Whipples |    | Second 1,000 Whipples |    |
|----------------------------|----------------------|----|-----------------------|----|
|                            | n                    | %  | n                     | %  |
| Periampullary              | 676                  | 68 | 667                   | 67 |
| Pancreas                   | 428                  | 43 | 473                   | 47 |
| Ampulla                    | 112                  | 11 | 81                    | 8  |
| Bile duct                  | 98                   | 10 | 76                    | 8  |
| Duodenum                   | 38                   | 4  | 37                    | 4  |
| Pancreatitis               | 86                   | 9  | 44                    | 4  |
| IPMN*                      | 33                   | 3  | 80                    | 8  |
| Neuroendocrine             | 49                   | 5  | 55                    | 6  |
| Ampullary/duodenal adenoma | 48                   | 5  | 51                    | 5  |
| Cystadenoma                | 35                   | 4  | 33                    | 3  |
| Metastasis to pancreas     | 7                    | 1  | 7                     | 1  |
| GIST                       | 4                    | 0  | 5                     | 1  |
| Miscellaneous              | 62                   | 6  | 58                    | 6  |

# Ressecção






## Arteries of Liver, Pancreas, Duodenum and Spleen






## Arteries of Duodenum and Head of Pancreas



Reflected to Left




- Etapas do procedimento













Third  
portion of  
duodenum

Superior  
mesenteric v.












# Reconstrução


- Pâncreas
- Via biliar
- Estômago


## Ducto mucosa





Ducto mucosa




























## Via biliar



# Estômago



b

Received: 2016.07.27  
Accepted: 2016.09.16  
Published: 2016.XX.XX

ISSN 1941-5923  
© Am J Case Rep, 2016; 17:  
DOI: 10.12659/AJCR.900792

## Performance of Laparoscopic Pancreatoduodenectomy For Solid Pseudopapillary Tumor of Pancreas

Authors' Contribution:  
Study Design A  
Data Collection B  
Statistical Analysis C  
Data Interpretation D  
Manuscript Preparation E  
Literature Search F

ABCDEF 1 **Orlando Jorge M. Torres**  
ADF 1 **José Maria A. Moraes Junior**  
AEF 1 **Anmara Moura Moraes**  
AEF 1 **Camila Cristina S. Torres**  
ABCD 2 **Antonio Talvane T. Oliveira**

1 Department of Digestive Surgery, Federal University of Maranhão, São Luiz, MA, Brazil

2 Department of Digestive Surgery, Barretos Cancer Hospital, Barretos, SP, Brazil

Laparoscópica

# Complicações

**Table 4.** Morbidity

| <b>Complication</b>              | <b>n</b> | <b>%</b> |
|----------------------------------|----------|----------|
| Delayed gastric emptying         | 410      | 21       |
| Postoperative pancreatic fistula | 295      | 15       |
| Wound infection                  | 222      | 11       |
| Cardiac event                    | 69       | 3        |
| Pneumonia                        | 38       | 2        |
| Delayed bleeding                 | 32       | 2        |
| Chyle leak                       | 28       | 1        |
| Any complication                 | 894      | 45       |

# MANAGEMENT OF POSTOPERATIVE PANCREATIC FISTULA BY LIGATION OF THE PANCREATIC DUCT

Orlando Jorge Martins **TORRES**, Alzira de Alencar Lima **LINS**, Paulo Márcio Sousa **NUNES** and Itaguacy Rodrigues **COELHO**

ABCDDV/298

Torres OJM, Lins AAL, Nunes PMS, Coelho IR. Management of postoperative pancreatic fistula by ligation of the pancreatic duct. **ABCD Arq Bras Cir Dig**, São Paulo, 14(2): 101-103, 2001.

**ABSTRACT** - Pancreatic fistula is a serious and potentially lethal complication after pancreaticoduodenectomy.




FIGURE 1 - Pancreaticojejunostomy and anastomotic leak




FIGURE 2 Closure of jejunal stump and pancreatic duct ligation.

# Radioterapia

- 45-46 Gy em frações de 1,8-2 Gy  
Leito, anastomoses e Ln adjacentes
- 5-9 Gy  
Leito, anastomoses
- \*\*\*\*\*

# Tratamento paliativo

- Duodenopancreatectomia
- Icterícia
  - Prótese endoscópica
  - Prótese por intervenção
  - Cirurgia
    - Aberta
    - Laparoscopia
- Obstrução gástrica
- Dor
- Melhorar qualidade de vida

**Table 70.1** Pancreatic cancer: clinical problems and palliative methods.

---

*Biliary obstruction*

Endoscopic methods (ERCP and EUS)

Percutaneous transhepatic cholangiography (PTC)

Combined ERCP and PTC

*Gastric outlet obstruction*

Endoscopic

Percutaneous

*Abdominal pain*

EUS-guided neurolysis

Percutaneous neurolysis

ERCP drainage of pancreatic duct obstruction

---


ERCP, endoscopic retrograde cholangiopancreatography; EUS, endoscopic ultrasound.



# Ictericia

Table 70.2 Approaches to palliation of obstructive jaundice.


|              | Advantages   | Disadvantages   |
|--------------|--|---|
| Surgical     | Lifelong palliation usual<br>Simultaneous palliation of gastric outlet obstruction<br>Simultaneous palliation of pain (intraoperative nerve block) | Most invasive<br>Morbidity and mortality  |
| Percutaneous | Nonsurgical  | Pain, bleeding<br>External drains   |
| Endoscopic   | Nonsurgical<br>Relatively painless<br>Outpatient treatment possible  | Stents may occlude<br>Expertise variable<br>Complications (perforation, pancreatitis, bleeding) |


# Prótese endoscópica






## Anastomose colédoco-duodenal






Anastomose hepático-jejunal  
em Y de Roux



# Obstrução duodenal

- 15-20% obstruem
- Gastrojejunو paliativa desnecessária







CB-IHPBA 2017



PORTO ALEGRE

## VIII CONGRESSO BRASILEIRO DE CIRURGIA DO FÍGADO, PÂNCREAS E VIAS BILIARES

SAVE THE DATE

7 a 9 de setembro de 2017

Participe do mais importante Congresso  
de Cirurgia do Fígado, Pâncreas  
e Vias Biliares do país.

Prepare seus temas livres.

[www.cb.ihpba.com.br](http://www.cb.ihpba.com.br)